Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer

NCT ID: NCT02417662

Last Updated: 2024-10-28

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 340 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-08-19
• Study Completion Date: 2028-08-31

Brief Summary

The trial will assess the addition of stereotactic ablative radiotherapy (SABR) to standard anti-cancer therapy (SACT) in patients with oligometastatic non-small cell lung cancer. Patients will be randomised to receive either standard treatment alone (SACT) or standard treatment with conventional radiotherapy (RT) and SABR.

Detailed Description

SARON is a confirmatory phase III study examining the efficacy and safety of stereotactic ablative radiotherapy (SABR) and conventional radiotherapy (RT) alongside standard chemotherapy in patients with oligometastatic non-small cell lung cancer.

Current treatment for this group of patients is systemic anti-cancer therapy. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines. There is sufficient evidence regarding the safety of SABR, its effect on local control and a possible impact on overall survival. This trial will further examine overall survival, progression free survival and local control, as well as toxicity, feasibility, patient reported outcomes and health resource use.

There will be a feasibility analysis performed after 50 patients have been randomised. This will assess the practicality of achieving recruitment targets, logistics of delivering the experimental treatment and the potential for contamination (as patients may seek SABR outside of the trial if randomised to the non SABR arm). There will also be a parallel thoracic SABR safety and feasibility study after recruitment and treatment of 20 patients with thoracic metastases.

This is a multicentre randomised phase III study based on patients with oligometastatic NSCLC.

Trial arms:

Control Arm: systemic anti-cancer therapy alone (SACT) Experimental Arm: SACT plus radical RT to primary and SABR and/or SRS to metastases

Conditions

Non-small Cell Lung Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Systemic Anti-Cancer Therapy (SACT) alone

The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.

Group Type: ACTIVE_COMPARATOR

Non-investigational SACT

Intervention Type: OTHER

There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.

SACT + Radical Radiotherapy (Conventional RT and SABR)

SACT followed by radical RT (conventional or SABR) to the primary and SABR to the metastatic sites.

The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.

Group Type: EXPERIMENTAL

Radical Radiotherapy (Conventional RT and SABR)

Intervention Type: RADIATION

Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases

Interventions

Radical Radiotherapy (Conventional RT and SABR)

Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases

Intervention Type: RADIATION

Non-investigational SACT

There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Patient ≥ 18 years

2. Histologically or cytologically confirmed NSCLC.

3. Staging with FDG PET-CT whole body scan and MRI brain within 45 days prior to registration (but prior to commencement of first cycle of SACT). [Note: Brain CT with IV contrast can be performed instead (within 45 days prior to registration). However, if brain metastases are evident on the brain CT then a brain MRI must be performed prior to randomisation, i.e. the Brain CT is sufficient for registration into the trial but not for randomisation if it is positive for brain metastases, in which case a brain MRI must be performed]

4. ECOG performance status 0 to 1 (prior to commencement of first cycle of SACT).

5. Patient presenting with primary disease +/- lymph nodes and synchronous oligometastatic disease (1-5 lesions in up to a maximum of 3 organs).

6. Patient is deemed fit to receive four cycles of systemic anti-cancer therapy, according to local guidelines and assessment.

7. Patient is deemed fit to receive radical RT (either conventional RT or SABR) to primary disease +/- lymph node and SABR/SRS to 1-5 metastases according to local guidelines and assessment.

8. Primary tumour +/- lymph node suitable for radical RT (either conventional RT or SABR).

9. 1-5 metastatic lesions in up to a maximum of 3 organs, assessable according to RECIST v1.1 and all of which are suitable for SABR/SRS (only one site of metastasis or primary tumour needs to be measurable according to RECIST v1.1).

i. If brain metastasis present, the NHS commissioning guidelines need to be met for intracranial SRS (≤20 cc) (or equivalent for Wales, Scotland & Northern Ireland in line with standard of care).

ii. Lymph nodes included in the N1-3 categories of the IASLC 2009 staging criteria are treated in the conventional radiotherapy volume and are not counted as metastases.

iii. Lymph nodes not included in the N1-3 categories of the IASLC 2009 staging criteria, e.g. pelvic lymph nodes, are counted as metastases.

iv. For bone metastases pre-SABR stabilisation should be considered as clinically appropriate. This does not exclude the patient from the study.

10. Acceptable lung function for radical lung radiotherapy as assessed according to local policy. Note: Potential thoracic sub-study patients will need to complete pulmonary function tests pre-randomisation

11. No relevant co-morbidities, including UIP pulmonary fibrosis and connective tissue disorders.

Additional inclusion Information Patients with lung cancer and an additional malignant nodule are difficult to categorise, and the current stage classification rules are unclear. Such patients should be evaluated by the local multidisciplinary team to determine whether the additional lesion represents a second primary lung cancer or an additional tumour nodule corresponding to the dominant cancer. The SARON TMG will accept local MDM decisions on this and will centrally review all baseline imaging retrospectively

Exclusion Criteria

1. Patient has had palliative radiotherapy to any tumour site prior to registration or requires palliative radiotherapy prior to randomisation.

2. Presence of an actionable molecular aberration.

3. Patients currently receiving VEGF inhibitors.

4. One or more metastases previously treated with alternative ablative treatment.Note: Surgical ablation (partial or total excision biopsy) is permitted for palliative or diagnostic purposes (e.g. for molecular analysis). Treatment for any residual disease/tumour bed will be at the discretion of treating clinician/MDT. Resected/ablated metastases will count towards the total number of metastases.

5. Patient has received any previous treatment for this NSCLC malignancy.

6. Patients who present with brain metastasis only and no sites of extra cranial metastatic disease i.e. the presence of more than 4 brain metastases is an exclusion criterion.

7. Metastasis in sites where normal radiotherapy OAR constraints cannot be met.

8. Brain metastasis within the brainstem.

9. Patients who have more than five sites of metastases in up to 3 organs prior to trial registration.

10. Primary tumour or metastases causing direct invasion or high clinical suspicion of direct invasion of the wall of a major blood vessel, oesophagus, trachea, proximal bronchial tree, stomach, intestines or mesenteric lymph nodes or cutaneous metastases or diffuse serosal metastases.

11. Malignant pleural or pericardial effusion.

12. Bilateral adrenal metastases.

13. History of prior malignant tumour likely to interfere with the protocol treatment, (patients without evidence of disease for at least 1 year or a non-melanoma skin tumour or early cervical cancer are eligible).

14. Women who are pregnant or breast feeding.

15. Stage III disease with extensive nodal disease not treatable in radical radiotherapy field.

16. Leptomeningeal disease

Eligibility Criteria for Randomisation

Following cycle 2 of induction SACT, patients must meet the following eligibility criteria for randomisation:

• No confirmed disease progression on post-cycle 2 CT scan (according to RECIST v1.1)

• Patients with up to 5 metastases at the time of registration but less than 5 visible after induction SACT are still eligible for randomisation.
• Patients with no visible metastases following 2 cycles of induction of SACT are eligible for randomisation. If randomised to the Investigational Arm, these patients will receive RT upon relapse of metastases (patients who experience progression with new metastases are not eligible for randomisation or for trial treatment).
• Patients with complete response of the lung primary +/- lymph nodes following 2 cycles of induction SACT are eligible for randomisation. Patients randomised to the Investigational Arm, should receive conventional RT to the pre-SACT involved nodal stations and to any scar residuum at the primary site.
• Patients who progress following 2 cycles of induction of SACT cannot be randomised. Only overall survival data will be collected for these patients.
• ECOG Performance Status 0-2.
• Continued suitability for trial treatment as deemed by the treating clinician.
• Continues to meet all registration eligibility criteria, as detailed in section 6.4.1 (with the exception of ECOG status).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cancer Research UK

OTHER

Sponsor Role: collaborator

University College, London

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Fiona McDonald

Role: PRINCIPAL_INVESTIGATOR

Royal Marsden NHS Foundation Trust

Locations

UCLH

London, England, United Kingdom

Belfast City Hospital

Belfast, , United Kingdom

Queen Elizabeth Hospital

Birmingham, , United Kingdom

Bristol Royal Infirmary

Bristol, , United Kingdom

Addenbrooke's Hospital

Cambridge, , United Kingdom

BEATSON

Glasgow, , United Kingdom

Royal Surrey County Hospital

Guildford, , United Kingdom

St James's University Hospital

Leeds, , United Kingdom

Leicester Royal Infirmary

Leicester, , United Kingdom

Guy's and St Thomas's Hospital

London, , United Kingdom

St Bart's Hospital

London, , United Kingdom

The Royal Marsden Hospital

London, , United Kingdom

Christie Hospital

Manchester, , United Kingdom

Clatterbridge Cancer Centre

Metropolitan Borough of Wirral, , United Kingdom

The James Cook University Hospital

Middlesbrough, , United Kingdom

Freeman Hospital

Newcastle, , United Kingdom

City Hospital

Nottingham, , United Kingdom

Weston Park Hospital

Sheffield, , United Kingdom

Southampton General Hospital

Southampton, , United Kingdom

Countries

United Kingdom

References

Conibear J, Chia B, Ngai Y, Bates AT, Counsell N, Patel R, Eaton D, Faivre-Finn C, Fenwick J, Forster M, Hanna GG, Harden S, Mayles P, Moinuddin S, Landau D. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open. 2018 Apr 17;8(4):e020690. doi: 10.1136/bmjopen-2017-020690.

Reference Type: DERIVED

PMID: 29666135 (View on PubMed)

Other Identifiers

UCL/13/0594

Identifier Type: -

Identifier Source: org_study_id